Back to top
more

DURECT (DRRX)

(Delayed Data from NSDQ)

$1.35 USD

1.35
43,995

-0.12 (-8.16%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $1.36 +0.01 (0.74%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 29.41% and 12.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

VAXART (VXRT) delivered earnings and revenue surprises of -400% and 90.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging DURECT (DRRX) This Year?

by Zacks Equity Research

Here is how Durect (DRRX) and Elevance Health (ELV) have performed compared to their sector so far this year.

Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -19.05% and 33.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

CARISMA THERAP (CARM) delivered earnings and revenue surprises of -24.32% and 12.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

DURECT (DRRX) delivered earnings and revenue surprises of 25% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

MediWound (MDWD) delivered earnings and revenue surprises of 17.39% and 0.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Matches Q4 Earnings Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 0% and 0.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -2.22% and 27.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Think Durect (DRRX) Could Surge 594.98%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Durect (DRRX) points to a 595% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -4% and 41.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 13.21% and 2.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 0% and 11.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -25% and 59.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Q2 Earnings Lag Estimates

by Zacks Equity Research

United Therapeutics (UTHR) delivered earnings and revenue surprises of -41.22% and 0.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 0% and 21.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Alpine Immune Sciences, Inc. (ALPN) Soars 6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 40% and 204.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Zogenix (ZGNX) delivered earnings and revenue surprises of -8.89% and 1.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Durect (DRRX) is Poised for a Turnaround After Losing 17.1% in 4 Weeks

by Zacks Equity Research

Durect (DRRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -0.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Durect (DRRX) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.